535
edits
Changes
no edit summary
In the SensUs Competition, a saliva based test will be developed. Moreover, SensUs strives to develop sensors that provide results within 5 minutes and that are as sensitive as possible.'''The SensUs Competition aims to innovate the field of influenza biosensing by using saliva as a matrix, by the speed of the test, and by targeting a high sensitivity. '''
{| class="wikitable" style="margin-bottom:0"
|NS, NPS, NPA, NPW direct, NP, NPA, NPW in VTM
|1.63*10<sup>3</sup>-4.4*10<sup>3</sup>
|-
|Princeton BioMeditech Corp.<ref name="Arti22">BioSing RIDT Product Information, Princeton BioMeditech Corp., http://punchout.medline.com/product/BioSign-Rapid-Flu-AB-Antigen-Panel-Test-by-Princeton-BioMeditech/Influenza-Testing/Z05-PF176440?question=&index=P11&indexCount=11#mrkSpec</ref>
|BioSign® Flu A & B
LABSCO
|Yes
|N/A
|89,2%
|99,4%
|NS, NPS direct, NPA(waived), NPW(not waived)
|N\A
|}<div style="margin-bottom:1em"><sub>''Table 2: Selection of currently available systems for measuring adalimumab.''<br />*Note: the dilution ratio is defined as 1:x, with x the volume of added reagents relative to the volume of plasma sample</sub></div>
